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Abstract Ceramide, generated during sphingomyelinase-in- 
duced sphingolipid cleavage, is considered an important mediator 
in cytokine signaling. The effects of endogenously generated and 
exogenously delivered ceramide on long-term insulin secretion 
and replication by pancreatic E-cells were investigated, and com- 
pared to the effects of interleukin I~ (IL-I~). Generation of 
/3-cell ceramide by exogenous phingomyelinase, or addition of 
cell-permeant ceramide analogs C2-ceramide and C6-ceramide, 
caused inhibitory effects on E-cell insulin production and mito- 
genesis mimicing those evoked by IL-I~. Hence, ceramide may 
be involved in transducing the cytostatic and cytotoxic actions of 
IL- I~ in the E-cell. 
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I. Introduction 
The ability of the insulin-producing pancreatic fl-cell to ex- 
pand its proliferative capacity to accomodate an increased need 
for insulin might to be of significance for the development of
diabetes mellitus, because this disease in characterized by a 
reduced fl-cell mass [1]. Also in different animal models for both 
insulin-dependent a d non insulin-dependent diabetes does a 
defect fl-cell regeneration seem to be of central importance in 
the development of glucose intolerance. Thus, it has been 
shown that administration ffl-cell specific toxins, e.g. strepto- 
zotocin and alloxan, which results in destruction ofthe majority 
of ,B-cells and subsequent hyperglycemia, is not accompanied 
by a compensatory egeneration offl-cells [1]. In addition, in 
the genetic model for insulin-dependent diabetes, the db/db 
mouse, fl-cell regeneration is not a noteworthy component [1]. 
Furthermore, xperimental diabetes in rodents may be allevi- 
ated by transplantation f pancreatic slet grafts, however e- 
quiring a large number of islets [1]. More recently it has been 
shown that the endogenous fl-cell mass can be expanded by 
autocrine/paracrine factors induced by 'cellophane wrapping' 
of the pancreas, a maneuver that not only induces anesidioblas- 
tosis-like state but importantly enough also ameliorates xper- 
imental diabetes mellitus [2]. 
Despite the potential importance of an insufficient extent of 
fl-cell replication in diabetes, not much is known about the 
intracellular mechanisms that normally govern this event, al- 
though some extracellular factors stimulating fl-cell DNA syn- 
thesis in vitro have been identified (reviewed in [1,3,4]). How- 
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ever, far less attention has been paid to the factors that inhibit 
fl-cell function and mitosis, in spite of the fact that such factors 
may be of regulatory significance. Nonetheless, much interest 
has been focused on interleukin-lfl (IL-lfl), a cytokine known 
to be produced by islet-infiltrating macrophages preceding the 
onset of type-1 diabetes mellitus [5]. IL-lfl exerts cytotoxic and 
suppressive actions on the fl-cell in vitro and is believed to 
occupy a pivotal role in triggering the outbreak of type-1 diabe- 
tes mellitus which is characterized byprogressive necrosis of the 
fl-cells by autoimmune processes [5,6]. 
There is compelling recent evidence that ceramide, a product 
of sphingomyelin hydrolysis, may function as a novel second 
messenger in conveying cytotoxic signals by effector molecules 
such as IL-lfl in other cell systems (reviewed in [7-9]). In this 
study, we compared the effects of IL-lfl and ceramide, ex- 
ogenously delivered or endogenously generated, on fl-cell insu- 
lin production and mitogenesis in vitro. 
2. Materials and methods 
2.1. Mater&Is 
Recombinant human IL-1,8 was graciously donated by Dr. Klaus 
Bendtzen, Laboratory of Medical Immunology, Rigshospitalet, Uni- 
versity Hospital, Copenhagen, Denmark. The biological activity of the 
IL-lfl was 5 U/pg, as determined bycomparison with an interim inter- 
national standard IL-lfl preparation (NIBSC, London, UK) in the 
mouse thymocyte costimulatory assay and the EL4 murine T-cell ine 
[10]. The endotoxin content after adding the interleukin at the highest 
concentration (25 U/ml) was < 1 pg/ml, as measured in the Limulus 
amoebocyte assay. We have previously found that neither 1 pg/ml nor 
10 pg/ml of endotoxin affected the growth or viability of insulin-pro- 
ducing cells [101. The cell-permeant ceramide analogs Cz-ceramide (D- 
erythro-2-acetamido-4-trans-sphingenine) a d C6-ceramide (D-erythro- 
2-hexylamido-4-trans-sphingenine) werepurchased from Matreya Inc., 
Pleasant Gap, PA. Sphingomyelinase (from Bacillus cereus) and o- 
sphingosine (from bovine brain) were obtained from Sigma Chemicals, 
St. Louis, MO, USA. Collagenase type CLS (EC 3.4.24.3) was obtained 
from Boehringer-Mannheim, Mannheim, Germany. Culture medium 
RPMI 1640, fetal calf serum, L-glutamine, bensylpenicillin a d strepto- 
mycin were from Flow Laboratories, Irvine, UK. Antibovine insulin 
serum was supplied by Miles-Yeda, Rehovot, Israel, whereas crystalline 
mouse insulin and [~25I]insulin were from Novo, Copenhagen, Den- 
mark. [methyl-3H]Thymidine (5 Ci/mmol) was purchased from Amer- 
sham International, Bucks. UK. Unisolve was from New England 
Nuclear, Boston, MA, USA and Soluene was provided by Packard 
Instruments, Downers Grove, IL, USA. All other chemicals of analyt- 
ical grade were obtained from E. Merck, Darmstadt, Germany. 
2.2. Preparation and culture of fetal islets 
Pregnant Wistar ats, purchased from B & K Inc. (Sollentuna, Swe- 
den), were killed by cervical dislocation on day 21 of gestation and the 
fetuses rapidly removed. Fetal rat islets were prepared from pancreatic 
glands as previously described [11-15]. Briefly, the pancreata were 
finely chopped and digested for a short time with collagenase. The 
carefully washed igest was plated in culture dishes allowing cell attach- 
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ment (Nunc, Roskilde, Denmark) and cultured for 5 days at 37°C in 
a humidified atmosphere of 5% CO2 in ambient air in medium RPMI 
1640 containing 11.1 mM glucose, 10% fetal calf serum, 2 mM L- 
glutamine, 100 U/ml bensylpenicillin a d 0.1 mg/ml streptomycin. At
the end of the culture period, groups of islets were transferred to fresh 
media containing 1% fetal calf serum and cultured free-floating over- 
night, a procedure that minimizes fibroblast proliferation. Spherical 
islets, free of connective tissue, were then selected under a stereo micro- 
scope and used for the different analyses listed below. In each experi- 
ment, all test groups received the same amount of solvent (EtOH). In 
order to enhance ceramide solubility and cellular accessibility, the ana- 
logs were complexed with BSA at 37°C 60 rain prior to addition to 
culture media. This was done by dissolving C2-ceramide , C6-ceramide 
or sphingosine in absolute thanol (25 raM) and diluting 1 : 25 with BSA 
(4 mg/ml). 
2.3. DNA synthesis 
Islets in groups of 50 were cultured for 24 h as described above. 
During the last 5 h, 1 aCi/ml of [methyL3H]thymidine was present in 
culture media. At the end of the labeling period the islets were washed 
in PBS, ultrasonically homogenized in redistilled water, and the acid- 
insoluble material precipitated inice-cold 10% trichloroacetic a id [12- 
15]. The precipitate was washed twice in trichloroacetic a id and dis- 
solved in 50/~1 of Soluene. The radioactivity incorporated was deter- 
mined by scintillation counting after addition of 1 ml of Unisolve. 
Given the long cell cycle of the E-cell [1] and the fact that unsynchron- 
ized cells were studied, it was considered necessary to expose the islets 
for 24 h to the different test substances, a procedure that allows DNA 
synthesis initiated prior to addition of test substances tobe terminated 
before [3H]thymidine addition. 
2.4. Islet insulin content and insulin accumulation 
The islet insulin content in homogenates xtracted overnight in acid 
ethanol [12 15] and insulin accumulation in culture media during the 
last 24 h of culture were determined radioimmunologically [16]. 
3. Results 
As shown in Fig. 1, the addition of IL-lfl (25 U/ml) caused 
a marked suppression of long-term (24 h) accumulation of 
insulin in the culture medium, thus confirming previous reports 
[6,17]. There was a corresponding slight decrease in the islet 
insulin content, an effect which however did not attain statisti- 
cal significance in this series (Fig. 2). Moreover, as demon- 
strated in earlier work [13,18], IL-lfl also decreased fl-cell mito- 
genesis, as monitored by measurements of [3H]thymidine into 
DNA (Fig. 3). This effect of IL-lfl, and the inhibited secretion, 
were mimiced by exogenous phingomyelinase (i U/ml; Figs. 
1 and 3). By contrast, the effect of sphingomyelinase on the islet 
content of insulin was not significantly different from that of 
controls (Fig. 2). Addition of the cell-permeant ceramide ana- 
logs (C2-ceramide and C6-ceramide, 15 ¢tM each) complexed 
with BSA to the culture media resulted in more pronounced 
cytotoxic effects, as evidenced by increased accumulation of 
insulin in culture media (taken to reflect cell leakage; Fig. 1), 
decreased cellular insulin content (Fig. 2) and inhibition of cell 
proliferation (Fig. 3). In addition, light microscopical inspec- 
tion of islets after 24 h of culture with C2-ceramide and C 6- 
ceramide revealed signs of gross cytotoxicity (not shown). In 
contrast, equimolar concentrations of sphingosine caused small 
stimulatory effects, which, however, were not entirely consis- 
tent (not shown). 
4. Discussion 
The present study shows that exogenously delivered cer- 
amide analogs capable of entering the cell, as well as generation 
of endogenous ceramide by addition of exogenous sphingomy- 
elinase, evoke cytotoxic effects and inhibits fl-cell function. 
Similar effects were recorded in this study, and in many previ- 
ous reports [1,5,6,10,13,17,18], by exposure to the cytokine 
IL-lfl. There is much converging evidence to support a key 
effector role for IL-lfl in the development of type-1 diabetes 
mellitus. Hence, IL-lfl is secreted from leukocytes infiltrating 
the islets early in the development of insulin-dependent diabetes 
mellitus [5,6] and IL-1 levels in serum are elevated in newly 
diagnosed iabetic patients [19]. In addition, IL-lfl has been 
shown to exert both inhibitory and cytotoxic actions on pancre- 
atic islet cells in vitro [1,5,6,10,13,17,18], findings reproduced 
in the present study. 
A humongous amount of work has been done to pin down 
the mechanisms by which IL-lfl works, and according to the 
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Fig. 1. Effects of IL-lfl, sphingomyelinase nd ceramide analogs on insulin accumulation. Groups of 50 fetal rat islets were cultured free-floating 
for 24 h in medium RPMI 1640 containing 1% fetal calf serum and supplemented as indicated in the figure. The accumulation f insulin in the culture 
medium was determined radioimmunologically. Concentrations used were: IL-lfl, 25 U/ml; sphingomyelinase 1 U/ml; C:-ceramide and C6-ceramide, 
15 ~tM. Bars represent means _+ S.E.M. for 6 experiments. * and ** denote P < 0.05 and P < 0.01 for chance differences vs. controls using Student's 
paired t-test. 
,4. Sj6holm/FEBS Letters 367 (1995) 283-286 285 
1500" 
1000 
500 
~ A  
Control IL-lg Sphingomyelinas C2-ceramide C6-ceramide 
Fig. 2. Effects of IL-lfl, sphingomyelinase, ndceramide analogs on islet insulin content. Groups of 50 fetal rat islets were cultured free-floating for 
24 h in medium RPMI 1640 containing 1% fetal calf serum and supplemented as indicated in the figure. The insulin concentration in islet homogenates 
extracted inacid ethanol was determined radioimmunologically. Concentrations u ed were: IL-lfl, 25 U/ml; sphingomyelinase 1 U/ml; C2-ceramide 
and C6-ceramide, 15/IM. Bars represent means + S.E.M. for 6 experiments. * denotes P < 0.05 for a chance difference vs. controls using Student's 
paired t-test. 
contemporary conceptual framework a primary event is gener- 
ation of the noxious gas nitric oxide shutting down ATP pro- 
duction through inhibition of Krebs cycle enzymes [17]. Addi- 
tionally, however, generation of ceramide through the action 
of sphingomyelinase is a rapid and consistent event after expo- 
sure to IL-lfl and other cytokines, e.g. interferon- 7 and tumor 
necrosis factor ~ [8,9,2~22]. In contrast to the large wealth of 
information accumulating regarding products of phosphoinos- 
itide hydrolysis as regulatory molecules, the sphingolipids have 
been poorly appreciated and were until recently merely per- 
ceived as structural components of the plasma membrane. 
However, a rapidly growing body of evidence implicate cer- 
amide, generated through sphingomyelin hydrolysis, as a novel 
second messenger, conveying antiproliferative signals by cyto- 
toxic molecules such as IL-1 (reviewed in [7-9,22]). It is note- 
worthy that ceramide seems to counteract the effects of the 
phosphoinositide cleavage product diacylglycerol, the latter 
being an activator of protein kinase C and linked to growth 
promotion [23,24]. Thus, although ceramide reportedly does 
not inhibit protein kinase C, it has emerged as a second messen- 
ger mediating rowth suppression and apoptosis [7-9,22] and 
may well prove to be as paramount as diacylglycerol in regula- 
tion of cell signaling. Additionally, specific targets for ceramide 
have been identified, including activation of a serine/threonine 
protein phosphatase of the 2A subfamily [25,26], the latter 
recently being identified by us in fl-cells [27,28]. Entirely con- 
sistent with our present results are the previous findings that 
specific inhibition of serine/threonine protein phosphatase 2A 
with low concentrations of okadaic acid [28] or protein kinase 
C stimulation with phorbol ester [24,28,29] promotes insulin 
secretion. Conversely, nanomolar concentrations of okadaic 
acid or phorbol ester prevent apoptosis and c-myc downregula- 
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Fig. 3. IL-lfl and ceramide decrease fl-cell proliferation. Groups of 50 fetal rat islets were cultured flee-floating for 24 h in medium RPMI 1640 
containing 1% fetal calf serum and supplemented as indicated in the Figure. During the final 5 h of culture, 1 pCi/ml [3H]thymidine was present in 
culture media nd DNA synthesis rates were determined by measuring the radioactivity incorporated into trichloroacetic a id-precipitable material. 
Concentrations u ed were: IL-lfl, 25 U/ml; sphingomyelinase 1 U/ml; C2-ceramide en C6-ceramide, 15/~M. Bars represent means _+ S.E.M. for 
6 experiments. ** and *** denote P < 0.01 and P < 0.001 for chance differences v . controls using Student's paired t-test. 
286 ,4. Sj6holmlFEBS Letters 367 (1995) 283-286 
tion evoked by ceramide [9]. Thus, ceramide and diacylglycerol 
appear to be the Yin and Yang of cellular signaling through 
their opposing effects on protein phosphorylation. 
The recent development of cell-permeant ceramide analogs 
has made elucidation of the role of ceramide in living cells 
become amenable and conclusive [9]. Hence, one of the analogs 
employed in this study, C2-ceramide, was shown to inhibit 
growth of leukemia cells and it appears that ceramide regulates 
the expression of c-myc levels and the transcription factor NF- 
KB, and is also able to interact with phospholipase A2 and 
cyclo-oxygenase [9], which are also affected by IL-1 [17]. 
Whether any of these elements are targeted by ceramide in the 
B-cell remains to be seen, and it surely also will be of interest 
to look into the possible interaction between ceramide and 
nitric oxide, i.e. whether ceramide acts uphill or downhill of 
nitric oxide. In this context, it is noteworthy that serum from 
patients with type I diabetes mellitus, whose B-cells are suc- 
cumbed by autoimmune assault, not only contains elevated 
levels of IL-1 [19] but also causes exaggerated Ca 2+ influx in 
insulin-secreting cells leading to DNA fragmentation character- 
istic of apoptosis [30], and that IL-1B activates apoptosis in 
these cells through nitric oxide generation [31], thus mimicing 
the actions of ceramide presently and previously [32] recorded. 
Our present findings not only show that exogenous ceramide 
suppresses B-cell growth and function, but also that artificially 
stimulating eneration of ceramide in the B-cell by addition of 
the normally membrane-bound enzyme sphingomyelinase gave 
rise to qualitatively similar results. This also mimicked the 
suppressive actions of IL-lfl, a pathophysiological effector of 
ceramide synthesis and B-cell death, thus adding further cre- 
dence to a role of ceramide as a second messenger mediating 
cytotoxic signals by molecules such as IL- lB. It should be noted 
that in another system [9], exogenous phingomyelinase mim- 
icked the actions of a cell-permeant ceramide analog, thus 
showing that ceramide can be formed intracellularly when 
sphingomyelinase i  added to the outside of the cell. 
It is concluded that ceramide, either delivered exogenously 
or generated endogenously, causes inhibitory and cytotoxic 
actions on the insulin-secreting pancreatic B-cell in vitro, effects 
that are mimicked by IL-lB. Hence, ceramide may be an impor- 
tant intracellular second messenger, conveying the suppressive 
and cytotoxic actions of IL-1B on the B-cell. 
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